Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis

Ganpeng Yu 1*, Wang Xiang 2,3, Tianqing Zhang 4,5, Liuting Zeng 6, Kailin Yang 7 and Jun Li 1*

Abstract

Background: Osteoarthritis (OA) is the commonest form of inflammatory joint disease. Unfortunately, to date, there is no appropriate treatment for OA. Boswellia serrata was considered as a potent anti-inflammatory, anti-arthritic and analgesic agent that may be a drug for OA.

Methods: In this meta-analysis, data from randomized controlled trials were obtained to assess the effects of Boswellia or its extract versus placebo or western medicine in patients with OA. The primary outcomes included visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function and lequesne index.

Result: Seven trials involving 545 patients were included. Compared with the control group, Boswellia and its extract may relieve the pain [VAS: (WMD -8.33; 95% CI -11.19, −5.46; P <0.00001); WOMAC pain: (WMD -14.22; 95% CI -22.34, −6.09; P = 0.0006)] and stiffness [WOMAC stiffness: (WMD -10.04; 95% CI -15.86, −4.22; P = 0.0007)], and improve the joint’s function [WOMAC function: (WMD -10.75; 95% CI -15.06, −6.43; P <0.00001); lequesne index: (WMD -2.27; 95% CI -3.08, −1.45; P <0.0001)].

Conclusion: Based on current evidence, Boswellia and its extract may be an effective and safe treatment option for patient with OA, and the recommended duration of treatment with Boswellia and its extract is at least 4 weeks.

Keywords: Boswellia, Boswellia extract, Osteoarthritis, Systematic review, Meta-analysis

Background

Osteoarthritis (OA) is an inflammatory joint disease that mainly damages articular cartilage. It is characterized by the degradation of articular cartilage and involving the entire joint tissue, which eventually leads to joint degeneration, fibrosis, fracture, defect and damage to the entire articular surface [1–3]. Epidemiological studies show that there are currently 355 million people with arthritis worldwide, and arthritis has become the world’s number one disabling disease. In China, as of 2015, there were 120 million people with arthritis in mainland China, with an incidence rate of about 13%, of which the number of people suffering from OA is the largest [4]. The management of patients with knee OA is mainly based on individualized and gradient treatment for the condition and severity of arthritis [5–7]. Among them, the drugs for OA pain are mainly non-steroidal anti-inflammatory drugs (NSAID) and specific (COX-2) cyclooxygenase II inhibitors [8]. However, these drugs may be expensive or cause stomach bleeding, and cannot repair cartilage and treat subchondral damage [8–10]. Therefore, due to the high incidence of NSAID-related adverse events, there is an urgent need for a safer and effective alternative to OA.

Boswellic acid is the active ingredient in Boswellia serrata; it has shown significant pharmacological activity...
in the treatment of inflammatory diseases such as rheumatoid arthritis, chronic bronchitis, asthma and chronic inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) [11, 12]. Current research showed that 3-O-Acetyl-11-keto-beta-boswellic acid (AKBA) is the one boswellic acid with strong pharmacological activity; for example, AKBA has a powerful inhibitory effect on 5-lipoxygenase (5-LOX) [13, 14]. Clinical studies have shown that Boswellia serrata extract not only has anti-inflammatory and anti-arthritis properties, but also improves pain and physical function [15–18]; in vitro experiments also show that Boswellia serrata extract can inhibit the expression of inflammatory factors such as adhesion molecules [19–23]. With regard to the safety of Boswellia serrata, studies showed that Boswellia serrata extract (such as 5-Loxin and Aflapin) does not have toxic side effects at higher doses [23–25]. These indicate that the active compound of Boswellia extract (AKBA) is safe based on current evidence [23, 25].

As potential anti-inflammatory drugs for OA, the efficacy of Boswellia and Boswellia Extract have been reported in a lot of clinical trials [14–17, 24, 26]. Since 2003 [15], many trials have explored the feasibility of Boswellia and its extracts for the treatment of OA. In the meantime, the latest randomized controlled trials (RCTs) have assessed the benefits and adverse events of Boswellia and its extract for OA. To the best of our knowledge, this is the first systematic review and meta-analysis estimating the effectiveness and safety of Boswellia and its extracts for OA. Therefore, we hope that the results of this systematic review and meta-analysis will provide better evidence for the clinical application of Boswellia and its extract in the treatment of OA.

Why it is important to do the review
Boswellia and its extract have theoretical benefits for cultured cells in vitro and experimental animals [19, 21–23, 25, 27]; although several meta-analyses have widely analyzed the effect of herb or dietary supplements on OA [28, 29], to our knowledge, there is no systematic review and meta-analysis focused on assessing the efficacy of Boswellia and its extract on OA. For example, Liu et al. [28] conducted a systematic review about dietary supplements for patients with osteoarthritis; of the studies it included, only three RCTs were about Boswellia and its extract. Meanwhile, its conclusions about Boswellia and its extract on OA failed to provide valuable reference information for clinical decision making. Another systematic review [29] only analyzed the RCTs before 2013. In 5 years, more RCTs about Boswellia and its extract on OA have been completed, which means that relevant conclusions need to be updated or confirmed. Therefore, this systematic review and meta-analysis focus on and summarizes available evidence from RCTs about the role of Boswellia and its extract in OA.

Materials and methods
Protocol
Systematic reviews and meta-analysis are carried out strictly in accordance with the protocol (CRD42018086785) and the PRISMA-guidelines (see Supplementary Materials) [30].

Search strategy and selection criteria
Web of Science, the Chinese Science and Technology Periodical Database (VIP), Wan Fang Database (Chinese Ministry of Science & Technology), EMBASE, Medline Complete, Chinese Biomedical Database (CBM), ClinicalTrials, the China National Knowledge Infrastructure Databases (CNKI), Pubmed, Cochrane Library (Until Issue 2, 2018) were searched with keywords “boswellic acid”, “Boswellia”, “Shallaki”, “Salai”, “aflapin”, “5-loxin” and “osteoarthritis”. The search period is from the establishment of the journal to January 2018.

Selection criteria
Participants
Human with specified diagnosis criteria of OA.

Intervention methods
Boswellia or its extract.

Comparison methods
Other treatments for OA, such as placebo or conventional medicine;

Outcomes
(1) Primary outcomes: visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function and lequesne index. (2) Secondary outcomes: WOMAC pain, WOMAC stiffness, WOMAC function at different points in time.

Study design
Randomized controlled trials (RCTs).

Information retrieval and data extraction method
Three researchers (Ganpeng Yu, Liuting Zeng and Kailin Yang) independently screened the literature based on protocol (CRD42018086785). The discrepancies between the three researchers would be resolved through discussion of all researchers. Literature retrieval is carried out according to the search strategy, the search strategy of Pubmed is shown in Table 1.

After literature retrieval, three researchers (Ganpeng Yu, Liuting Zeng and Kailin Yang) extracted data from the included literature according to a pre-designed table (including author, year of publication, number of cases, inclusion and exclusion criteria of patients, duration of intervention, etc.). The discrepancies between the three researchers would be resolved through discussion of all
researchers. The missing data in the literature would be obtained by contacting the author. If the author cannot be contacted, it would be estimated by the method provided by Cochrane Handbook 5.1.0 [31].

### Literature quality evaluation methods

The Cochrane collaboration’s tool for assessing risk of bias provided by Cochrane Handbook 5.1.0 was used to evaluate the quality of the RCTs [32]. The evaluation content includes random sequence generation, allocation result concealment, blind method, incomplete result data, selective report and other biases. Four researchers (Ganpeng Yu, Wang Xiang, Tianqing Zhang, Liuting Zeng and Kailin Yang) independently assessed the quality of the literature. The discrepancies between the three researchers would be resolved through discussion of all researchers.

### Statistical analysis

The RevMan5.3 software provided by the Cochrane collaboration network was used for system evaluation and meta-analysis. Enumeration data is represented by risk ratio (RR) and 95% confidence interval (CI), and measurement data is represented by mean deviation (MD) and CI. The heterogeneity between the results of the studies was tested by $X^2$. If the heterogeneity of the study is low ($P > 0.10, I^2 < 50\%$), the fixed effect model is used for analysis; otherwise ($P < 0.10, I^2 > 50\%$), the source of heterogeneity is analyzed first and then subgroup analysis or random effect model is adopted.

### Results

#### Results of the search

The total records identified through database searching and other sources were 513. Four hundred ninety-seven (497) were excluded based on the title and abstract and 16 for more detailed evaluation. After that, 7 studies were included [24, 26, 33–37], while 9 studies were excluded [15–18, 38–42] according to the inclusion criteria (Fig. 1). The 9 studies were Kimmmatkar 2003 [15], Chopra 2004 [38], Shah 2010 [17], Chopra 2013 [39], Perera 2014 [16], Belcaro 2015 [40], Bolognesi 2016 [41], Gupta 2011 [18], Badria 2002 [42].

#### Description of included trials

A total of 7 RCTs with 545 participants were included. Sengupta’s RCTs consist of 2 trial groups and 1 control group [24, 26]. According to the method of Cochrane Handbook 5.1.0, the control group was divided into two groups, matching the two trial groups (Sengupta 2008a and Sengupta 2008b; Sengupta 2010a and Sengupta 2010b) [31]. The characteristics of the RCTs were shown in Tables 2 and 3.

#### Risk of Bias in included studies

The summary and graph of risk of bias were shown in Fig. 2.

#### Sequence generation

Among the 7 included RCTs, three studies [35–37] adopted unclear randomization procedures, we therefore rated it as having an unclear risk of bias. The other RCTs described their randomization procedures: Sengupta 2010 [24], Sengupta 2008 [26] and Vishal 2011 [33] utilized the computer-generated randomization scheme, while Haroyan 2018 [34] used the treatment randomization code to draw randomization. Thus, these RCTs were thought to have low risks of bias.

#### Allocation concealment

Sengupta 2010 [24], Sengupta 2008 [26], Vishal 2011 [33] and Haroyan 2018 [34] described that the appearance, smell and color of drugs preparations were similar and organoleptically indistinguishable, which is an acceptable method of allocation concealment. Hence, they were rated as having low risks of bias. Karimifar 2017 [35], Notarnicola 2016 [36] and Notarnicola 2011 [37] did not describe an acceptable method of allocation concealment; therefore, they were rated as having an unclear risk of bias.

#### Blinding

For blinding of participants and personnel, although all RCTs claim to use blinding, only Haroyan 2018 [34], Notarnicola 2016 [36] and Notarnicola 2011 [37] described the implementation process of blinding. Thus, we gave a low risk of bias for them. The other RCTs were rated as having an unclear risk of bias for they did not describe the blind implementation process.

For blinding of outcome assessment, the statisticians in Sengupta 2010 [24], Sengupta 2008 [26] and Vishal

| Table 1 Search Strategy for Pubmed |
|-----------------------------------|
| **Database** | **Search Strategy** |
| Pubmed | (boswelling acid OR Boswellia OR Boswellia serrata OR Boswellia carterii OR Boswellia carteri OR Shallaki OR Salai OR allapin OR 5-loxin) AND (Osteoarthritises OR Osteoarthritides OR Osteoarthrosis OR Osteoarthoses OR Arthritis, Degenerative OR Arthritis, Degenerative OR Degenerative Arthritis OR Degenerative Arthritis OR Osteoarthrosis Deformans) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR placebo [tiab] OR drug therapy [sh] OR trial [tiab] OR groups [tiab] OR clinical trials as topic [mesh: noexp] OR Clinical Trial OR random* [tiab] OR random allocation [mh] OR single-blind method [mh] OR double-blind method [mh] OR cross-over studies) NOT (animals [mh] NOT humans [mh]) |
2011 [33] wasn’t blinded, hence, they were rated as having a high risk of bias. Haroyan 2018 [34], Notarnicola 2016 [36] and Notarnicola 2011 [37] described the implementation process of blinding, hence, we gave a low risk of bias for them. Karimifar 2017 [35] were rated as having an unclear risk of bias for they did not describe the blind implementation process.

Incomplete outcome data
The missing outcome data of all RCTs balanced in numbers across intervention groups with similar reasons for missing data across groups. We gave them low risks of bias.

Selective reporting
One RCT (Vishal 2011 [33]) failed to provide all outcomes mentioned in its protocols, thus we thought its risk of bias was high. The other RCTs provided their protocols, and all of the study’s pre-specified outcomes that are of interest in the review had been reported in the pre-specified way; their risks of bias were low.

Other potential bias
In the RCTs of Sengupta 2010 [24], Sengupta 2008 [26] and Vishal 2011 [33], their protocols noted three primary outcome parameters, which means that when \( p = 0.05/3 = 0.017 \), the difference is significant. Strictly speaking, the statistics of this study were not carried out correctly. Hence, their risks of bias were high. Similarly, in Haroyan 2018 [34]'s RCT, the difference is significant when \( p = 0.05 / 2 = 0.025 \). Its risk of bias was also high. Other sources of bias were not observed in other RCTs; therefore, the risks of other bias of them were low.
| Study               | Country | Sample size | Intervention                                   | Mean age (years) |
|---------------------|---------|-------------|-----------------------------------------------|------------------|
|                     |         |             | Trial group                                   | Control group    |
| Vishal 2011 [33]    | India   | 30          | Aflapin 100 mg                                | 53.2 ± 6.5       | 55.3 ± 8.8 |
| Sengupta 2008 [26]  | India   | 47          | S-Loxin 100 mg or 250 mg                      | 52.79 ± 8.47     | 52.43 ± 9.65 |
| Sengupta 2010 [24]  | India   | 38          | Aflapin 100 mg or S-Loxin 100 mg             | 52.4 ± 8.87      | 52.4 ± 7.5  |
| Haroyan 2018 [34]   | Armenia | 67          | Boswellic acid 150 mg + curcuminoids 350 mg | 57.91 ± 902      | 56.04 ± 8.55 |
| Karimifar 2017 [35] | Iran    | 26          | Boswellia + Elaeagnus Extraction              | 52.0 ± 8.74      | 52.96 ± 8.57 |
| Notarnicola 2016 [36]| Italy   | 54          | Boswellic acid 15 mg + Methylsulfonylmethane 10,000 mg | 58.7 ± 12.5 | 59.5 ± 13.7 |
| Notarnicola 2011 [37]| Italy   | 30          | Boswellic acid 7.5 mg + Methylsulfonylmethane 5000 mg | 63.4 ± 8.2 | 60.2 ± 8.6  |
| Study       | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Relevant outcomes                                                                 | Duration |
|------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------|
| Vishal 2011 [33] | 1. Participants must understand risks and benefits of the protocol and able to give informed consent 2. Male and female subjects of 40–80 years of age 3. Females of child bearing potential must agree to use an approved form of birth control and have a negative pregnancy test result 4. Unilateral or bilateral OA of the knee for more than 3 months 5. Visual Analogue Scale (VAS) score during the most painful knee movement between 40 and 70 mm after 7 day withdrawal of usual medication 6. Lequesne’s Functional Index (LFI) score greater than 7 points after 7 days of withdrawal of usual medication 7. Ability to walk 8. Availability for the duration of the entire study period | 1. History of underlying inflammatory arthropathy or severe rheumatoid arthritis (RA) 2. Hyperuricemia (greater than 440 umol/L) and/or past history of gout 3. Recent injury in the area affected by OA of the knee (past 4 months) and expectation of surgery in the next 4 months 4. Intra-articular corticosteroid injections within the last 3 months 5. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal (GI) haemorrhage, congestive heart failure, hypertension, hyperkalemia 6. Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders 7. High alcohol intake (greater than 2 standard drinks per day) 8. Pregnant, breastfeeding or planning to become pregnant during the study 9. Use of concomitant prohibited medication other than ibuprofen 10. Obesity: body mass index (BMI) more than 30 kg/m^2 | VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, adverse events | 4 weeks |
| Sengupta 2008 [26] | 5. Visual Analogue Scale (VAS) score during the most painful knee movement between 40 and 70 mm after 7 day withdrawal of usual medication 6. Lequesne’s Functional Index (LFI) score greater than 7 points after 7 days of withdrawal of usual medication 7. Ability to walk 8. Availability for the duration of the entire study period | 1. Subjects with inflammatory and any secondary arthritis 2. Moderate and severe synovitis (grades 2 and 3) tear of meniscus 3. Chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems 4. Allergic anamnesis and drug intolerance 5. Pregnant or nursing 6. History of substance abuse 7. Subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study 8. Subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within 3 months prior to the study | VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, MMP-3, adverse events | 12 weeks |
| Sengupta 2010 [24] | 2. Subject taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within 3 months prior to the study | 1. Subjects with inflammatory and any secondary arthritis 2. Moderate and severe synovitis (grades 2 and 3) tear of meniscus 3. Chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems 4. Allergic anamnesis and drug intolerance 5. Pregnant or nursing 6. History of substance abuse 7. Subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study 8. Subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within 3 months prior to the study | VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, adverse events | 12 weeks |
| Haroyan 2018 [34] | Patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee (M17, according to International Classification of Diseases (ICD-10) of bone joints, verified by radiography (Grade 1–3 by Kellgren-Lawrence radiographic grades). | 1. Subjects with inflammatory and any secondary arthritis 2. Moderate and severe synovitis (grades 2 and 3) tear of meniscus 3. Chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems 4. Allergic anamnesis and drug intolerance 5. Pregnant or nursing 6. History of substance abuse 7. Subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study 8. Subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within 3 months prior to the study | WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, adverse events | 12 weeks |
| Karimifar 2017 [35] | 1. Age of 40 to 80 years 2. Knee osteoarthritis in at least one knee for at least 6 months based on ACR (American College of Rheumatology) diagnostic criteria 3. Pain score > 4 based on VAS (visual analog scale) 4. LFI (Lequesne Pain and Function Index) > 7 5. Serum CRP (C-reactive protein) < 10 mg/dl and ESR (erythrocyte sedimentation rate) < 20 mg/dl, (6) grade 2 or 3 of Kellgren-Lawrence scale in knee radiography obtained within the last 6 months 7. Free of liver, renal, or cardiac dysfunction 8. No use of intra-articular glucocorticoids or hyaluronic acid preparations within the last 3 months 9. No use of systemic glucocorticoids within the last 3 months 10. Free of all other bone and joint | 1. Irregular use of capsules (less than 80% of total capsules) 2. No use of capsules for at least 3 days | VAS, Lequesne Index, adverse events | 4 weeks |
### Table 3 The characteristics of the included studies (Continued)

| Study          | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Relevant outcomes                                                                 | Duration |
|----------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------|
| Notarnicola    | 1. a diagnosis of OA of the knee according to the criteria of the American College of Rheumatology | 1. previous surgery of the affected knee; 2. disease processes such as rheumatoid arthritis, autoimmune diseases, systemic diseases, and tumors | VAS, Lequesne Index                                                               | 24 weeks |
| 2016 [36]      | 2. grade 3 Kellgren and Lawrence radiographic staging,16 in which the severity of the arthritis is assessed on a scale from 0 to 4, hypothesizing a sequential evolution from the manifestation of osteophytes through a reduction in the width of the joint space, to subchondral sclerosis and finally the formation of cysts; 3. frequent joint pain (several days a week) for at least 6 months before recruitment; 4. pain in the knee, scored at least 4 cm on a 10 centimetric visual analogic scale (VAS) (from moderate to severe pain), where 0 means no pain and 10 is the worst pain possible; 5. a score of > 2 on the Lequesne pain-function index (LI),18 The LI is an OA-specific validated questionnaire that poses a series of questions about pain in the knee (five questions on a scale from 0 to 2, where 0 indicates no pain and 2 intense pain), functional limitation (four questions, using the same scale), and maximum walking distance (one question, with a score from 0 to 6, where 0 indicates the ability to walk for an unlimited distance and 6, the inability to cover 100 m). The maximum worst final score was 24. |                                                                     |          |
|                | 1. a diagnosis of OA of the knee according to the criteria of the American College of Rheumatology | 1. previous surgery of the affected knee; 2. disease processes such as rheumatoid arthritis, autoimmune diseases, systemic diseases, and tumors | VAS, Lequesne Index                                                               | 24 weeks |
| 2011 [37]      | 2. grade 3 Kellgren and Lawrence radiographic staging,13 in which the severity of the arthritis is assessed on a scale from 0 to 4, hypothesizing a sequential evolution from the manifestation of osteophytes through a reduction in the width of the joint space, to subchondral sclerosis and finally the formation of cysts; 3. frequent joint pain (several days a week) for at least 6 months before recruitment; 4. pain in the knee, scored at least 2 cm on a 10 centimetric visual analogic scale (VAS), where 0 means no pain and 10 is the worst pain possible; 6. a score of > 2 on the Lequesne pain-function index (LI).14 The LI is a disease-specific validated questionnaire that poses a series of questions about pain in the knee (five questions on a scale from 0 to 2, where 0 indicates no pain and 2 intense pain), functional limitation (four questions, using the same scale) and maximum walking distance (one question, with a score from 0 to 6, where 0 indicates the ability to walk for an unlimited distance and 6, the inability to cover 100 m). The maximum worst final score was 24. |                                                                     |          |
Primary outcomes

Visual analogue score

Six RCTs [24, 26, 33–37] reported the changes of the visual analogue score (VAS) at the end of treatment. Due to the high heterogeneity (Tau² = 10.85, I² = 94%, P < 0.00001), we used random effect model. In this index, it can be found that in improving VAS, Boswellia is better (WMD -8.33; 95% CI -11.19, -5.46; P < 0.00001). (Fig. 3).

WOMAC

Four RCTs [24, 26, 34–35] reported the changes of WOMAC pain. Due to the high heterogeneity (Tau² =
According to the result, compared with the control group, Boswellia is better in improving WOMAC pain (WMD -14.22; 95% CI -22.34, −6.09; P = 0.0006). (Fig. 4).

Four RCTs [24, 26, 33, 34] reported the changes of WOMAC stiffness. Due to the high heterogeneity (Tau² = 44.40, I² = 97%, P<0.00001), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving WOMAC stiffness (WMD -10.04; 95% CI -15.86, −4.22; P = 0.0007). (Fig. 5).

Four RCTs [24, 26, 33, 34] reported the changes of WOMAC function. Due to the high heterogeneity (Tau² = 23.03, I² = 93%, P<0.00001), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving WOMAC function (WMD -10.75; 95% CI -15.06, −6.43; P<0.00001). (Fig. 6).

**Lequesne index**

Six RCTs [24, 26, 33, 35–37] reported the changes of lequesne index. Due to the high heterogeneity (Tau² = 0.55, I² = 47%, P = 0.07), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving Lequesne Index (WMD -2.27; 95% CI -3.08, −1.45; P<0.00001). (Fig. 7).

**Secondary outcomes**

**Pain**

Several RCTs reported Pain index (VAS and/or WOMAC pain) at week 4, 8, 12. The details of them were shown in Table 4 and Figure S1 ~ S6 (see Supplementary Materials).

**Stiffness**

Several RCTs reported Stiffness index (WOMAC stiffness) at week 4, 8, 12. The details of them were shown in Table 5 and Figure S7 ~ S9 (see Supplementary Materials).

**Adverse events**

Five studies [24, 33–35, 37] reported AEs. Three of them were excluded because they reported no events in both arms. According to the results, there is also not strong evidence that which one is safer because there was no statistical difference (RR 0.63; 95% CI 0.22, 1.83; P = 0.39) (Fig. 8).

**Discussions**

This systematic review and meta-analysis including 7 RCTs analyzes the effectiveness and safety of Boswellia and its extract for OA. Compared with the control group, Boswellia and its extract may relieve the pain (VAS and WOMAC pain) and stiffness (WOMAC stiffness), and improve the joint’s function (WOMAC function and lequesne index). In particular, since the doses of Boswellia and its extract reported in RCTs used for secondary outcomes analysis are 100–250 mg, based on the current evidence, pain, stiffness and joints’ function start to improve after 4 weeks of continuous Boswellia and its extract (at least 100–250 mg) intervention. While this finding seems promising, it should be interpreted with caution mainly due to the unclear risk of bias for selection bias (random sequence generation, allocation concealment) and attrition bias (incomplete outcome data), the high risk of bias for reporting bias (selective reporting), and the small number of participants.

Five studies [24, 33–35, 37] reported AEs. Three of them were excluded because they reported no events in both arms. According to the results, there is also not strong evidence that which one is safer because there was no statistical difference. However, safety studies conducted according to OECD guidelines and extensive acute and dose-dependent subchronic safety experiments on rats demonstrate that Boswellia and its extract does not exhibit toxic manifestations [23, 25], which
means Boswellia and its extract might be a safety treatment option. But the absence of information on AEs does not mean that the intervention is safe [43]. Thus, although based on current evidences, we consider that Boswellia and its extract is a relatively safe treatment, we cannot assure it. Future clinical trials are required to report AEs with more explanations [44]. Thus, although based on current evidences, we consider that Boswellia and its extract is a relatively safe treatment, we cannot assure it. Future clinical trials are required to report AEs with more explanations [44].

Although there were several meta-analyses that have been widely analyzed the effect of herb or dietary supplements on OA [28, 29], as far as we know, this systematic review and meta-analysis is the first one that focused on evaluating the efficacy and safety of Boswellia and its extract for patients with OA. Compared with similar previous works [28, 29], we included more RCTs (including [33–36]) about Boswellia and its extract; thus, our conclusions were more accurate and reliable. In particular, compared with the work of Cameron et al. [29], we not only verified some outcomes (such as WOMAC) but also provide the recommended duration and dosage of Boswellia and its extract and so on. However, there are still some deficiencies in this study. For example, the risk of bias of some RCTs are high; the number of RCTs is small; and the total sample size is not large enough. But despite these limitations, our study has some important findings: First, boswellia and its extract can improve the symptoms of OA patients, especially the stiffness and function of joints. Second, our study suggests that boswellia and its extract are safe for OA patients. Finally, our study provides a basis for future clinical trials and drug development.
| Secondary outcomes | Overall effect | Heterogeneity test | Statistical method | Studies (N) | Sample size (N) | Figure | Reference |
|--------------------|----------------|--------------------|--------------------|-------------|----------------|--------|-----------|
| VAS at 4 weeks     | −6.38, −10.20, −2.57 | 0.001 | 18.94 | 95% | <0.00001 | Random inverse variance | 4 | 238 | Fig S1 [24, 26, 33, 35] |
| VAS at 8 weeks     | −5.44, −8.8, −2.09 | 0.001 | 14.11 | 95% | <0.00001 | Random inverse variance | 4 | 299 | Fig S2 [24, 26, 36, 37] |
| VAS at 12 weeks    | −19.37, −23.90, −14.85 | <0.00001 | − | 43 | 0.15 | Fixed inverse variance | 2 | 127 | Fig S3 [24, 26] |
| WOMAC pain at 4 weeks | −6.91, −11.08, −2.74 | 0.001 | 15.85 | 85% | <0.00001 | Random inverse variance | 3 | 186 | Fig S4 [24, 26, 33] |
| WOMAC pain at 8 weeks | −11.05, −14.94, −7.17 | <0.00001 | 10.57 | 79 | 0.003 | Random inverse variance | 2 | 127 | Fig S5 [24, 26] |
| WOMAC pain at 12 weeks | −12.37, −19.47, −5.26 | 0.0006 | 58.02 | 97% | <0.00001 | Random inverse variance | 3 | 262 | Fig S6 [24, 26, 34] |
### Table 5: The stiffness index at week 4, 8, 12

| Secondary outcomes | Overall effect | Heterogeneity test | Figure | Reference |
|--------------------|---------------|--------------------|--------|-----------|
|                    | MD 95%CI      | P  Tau²  I² (%)  P |        |           |
| WOMAC stiffness at 4 weeks | $-5.10$ $-8.55, -1.64$ 0.004 8.23 64 0.03 | Random inverse variance 3 186 | Fig S7 [24, 26, 33] |
| WOMAC stiffness at 8 weeks | $-8.02$ $-11.75, -4.29$ <0.0001 7.64 60 0.06 | Random inverse variance 2 127 | Fig S8 [24, 26] |
| WOMAC stiffness at 12 weeks | $-10.97$ $-19.30, -2.63$ 0.010 82.6 99 <0.0001 | Random inverse variance 3 262 | Fig S9 [24, 26, 34] |
Table 6 the function index at week 4, 8, 12

| Secondary outcomes  | Overall effect | Heterogeneity test | Figure | Reference |
|---------------------|----------------|--------------------|--------|-----------|
|                     |                | Statistical method |        |           |
|                     |                | Studies (N)        |        |           |
|                     |                | Sample size (N)    |        |           |
| WOMAC pain at 4 weeks | − 7.18, − 10.56, − 3.80 | Random inverse variance | 3 | 186 | [24, 26, 33] |
| WOMAC pain at 8 weeks | − 8.95, − 13.56, − 4.35 | Random inverse variance | 2 | 127 | [24, 26] |
| WOMAC pain at 12 weeks | − 12.79, − 18.41, − 7.43 | Random inverse variance | 3 | 262 | [24, 26] |
and cases included in this study is insufficient; the heterogeneity of some outcomes is high; these all affect the accuracy of the conclusions. The heterogeneity may be related to the discrepancies in the pharmacological effects of different Boswellia preparations. This may result from the different standardization of Boswellia and its extract manufacturing process, dosage, duration of treatment, units of laboratory tests and races of the selected patients or other places. Meanwhile, the recommended duration and dosage of treatment should also be interpreted with caution because the pain, stiffness and function index between week 1 and week 4 and the dosage of Boswellia and its extract outside 100–250 mg were not reported. Additionally, since the quality of the RCTs is generally medium to low, all results should be interpreted more cautiously. Last but not least, further rigorously designed studies with high quality are needed to confirm the effectiveness and safety of Boswellia and its extract preparations for patients with OA.

Conclusion
This systematic review and meta-analysis showed that Boswellia and its extract may be a novel drug for patients with OA. Based on current evidence, the recommended duration and dosage of treatment with Boswellia and its extract is at least 100-250 mg 4 weeks. However, current RCTs have limitations, including the missing information of pain, stiffness and function index between week 1 and week 4 and small sample sizes. Meanwhile, since the quality of the RCTs is generally medium to low, we should formulate the conclusion more cautiously. More double-blind, large sample size RCTs of Boswellia and its extract for OA that reported pain, stiffness and function index before 4 weeks and the dosage of Boswellia and its extract outside 100–250 mg are needed in the future to confirm or modify the result of this work.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12906-020-02985-6.

Additional file 1.
Additional file 2.

Additional file 3.
Additional file 4.
Additional file 5.
Additional file 6.
Additional file 7.
Additional file 8.
Additional file 9.
Additional file 10.
Additional file 11.
Additional file 12.

Abbreviations
OA: Osteoarthritis; NSAIDs: Non-steroidal anti-inflammatory drugs; MMP: Matrix metalloproteinase; RCT: Randomized controlled trials; AE: Adverse events

Acknowledgments
Not applicable.

Authors’ contributions
GY, WX, LZ, KY are responsible for the study concept and design. GY, LZ, KY are responsible for the literature searching; GY, WX, TZ, LZ, KY and JL are responsible for data analysis and interpretation; GY, WX, TZ, LZ, KY drafted the paper; GY and JL supervised the study; all authors participated in the analysis and interpretation of data and approved the final paper. GY and WX should be considered joint first author. GY and JL should be considered corresponding authors.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The Department of Orthopaedics, People’s Hospital of Ningxiang City, Ningxiang 410600, Hunan Province, China. 2 Graduate College, Guilin Medical University, Guilin, Guangxi Province, China. 3 Department of Rheumatology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Province, China. 4 Graduate College, University of South China, Hengyang, Hunan Province, China. 5 Department of Cardiology, The First Affiliated Hospital of University of South China, Hengyang, Hunan Province, China. 6 Graduate College, Hengyang Medical College, Hunan Institute of Technology, Hengyang, Hunan Province, China. 7 Department of Orthopaedics, People’s Hospital of Ningxiang City, Ningxiang 410600, Hunan Province, China.
College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China.

Received: 3 February 2020 Accepted: 9 June 2020
Published online: 17 July 2020

References
1. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin N Am. 2004;42:1–9.
2. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–46.
3. Karen WB, Iavid K, Arden N, et al. Regular review: medical management of osteoarthritis. BMJ. 2000;321:936–40.
4. Beringer A, Mloospec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491–501. https://doi.org/10.1038/s41584-019-0243-5.
5. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541–6. https://doi.org/10.1002/art.1780381104.
6. Anonymous. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43: 1905–1915.
7. Pendleton A, Arden N, Dougados M, et al. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105:31S–8S.
8. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998;104:23S–9S.
9. Wright JM. Double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002; 43: 1905–1915.
10. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of β boswellic acids inhibit TNFa production and blocks MAPK/NFκB activation in lipopolysaccharide induced THP-1 human monocytes. J Food Lipids. 2009;16:325–44.
11. Krishnarju AV, Sundaranaraj D, Vamsikrishna U, et al. Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20:556–63.
12. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Lovastatin and Aflapin® against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7:366–77.
13. Lallithakumari K, Krishnaraju AV, Sengupta K, et al. Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-β-sesquiterpene lactone (AKBA)-enriched Boswellia serrata extract (5-Loxin). Toxicol Mech Methods. 2006;16:199–226. https://doi.org/10.1080/15735620600620232.
14. Sengupta K, Krishnaraju AV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10:R85.
15. Gayathri B, Manjula N, Vinayakumar KS, et al. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases, Int Immunopharmacol. 2007;7:473–82.
16. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167–75. https://doi.org/10.1136/bjsports-2016-097333.
17. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014;22:CD002947. https://doi.org/10.1002/14651858.CD002947.pub2.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.
19. Sheets JJ, Higgins JP, Altman DG. Chapter 16: special topics in statistics. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011.
20. Sheets JJ, Higgins JP, Altman DG. Chapter 8: assessing risk of bias in included studies. In: Higgins JP Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. UK: The Cochrane Collaboration; 2011.
21. Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8:615–22.
22. Haroyan A, Mukuchyan V, Mkrtchyan N, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med. 2018;18:17. https://doi.org/10.1186/s12906-017-2062-z.
23. Karimifar M, Soltani R, Hajhashemi V, et al. Evaluation of the effect of Elaeagnus angustifolia alone and combined with Boswellia thurifera compared with ibuprofen in patients with knee osteoarthritis: a randomized double-blind controlled clinical trial. Clin Rheumatol. 2017;36:1849–53. https://doi.org/10.1007/s12325-017-3603-z.
24. Notaniocla A, Macagnano G, Moretti L, et al. MethyIsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: randomized trial. Int J Immunopathol Pharmacol. 2016;29:140–6. https://doi.org/10.1177/0394632015622215.
25. Notaniocla A, Tafuri S, Fusaro L, et al. The "MESACA" study: methyIsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011;28:894–906. https://doi.org/10.1007/s12261-011-0068-3.
26. Chopra A, Lavin P, Patwardhan B, Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J Clin Rheumatol. 2004;10(5):236–45.
27. Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narisumul G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial. Rheumatology (Oxford). 2013;52(8):1408–17. https://doi.org/10.1093/rheumatology/ket441. Pubmed 2013 Jan 30.
28. Belcaro G, Dugalli M, Luzzi R, Lleda A, Pellegrini L, Hu S, Ipolito E. Management of osteoarthritis (OA) with the pharma-standard supplement FlexiQuile (Boswellia): a 12-week registry. Minerva Gastroenterol Dietol. 2015; 22 [Epub ahead of print].
41. Bolognesi G, Belcaro G, Feragalli B, Cornelli U, Cotellese R, Hu S, Dugall M. Movardol® (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study. Eur Rev Med Pharmacol Sci. 2016;20(24):5198–204.

42. Badria FA, et al. Boswellia-Curcumin Preparation for Treating Knee Osteoarthritis: A Clinical Evaluation. Alter and Comple Therap. 2002;12:341–8.

43. Loke Y, Price D, Herxheimer A. Chapter 14: adverse effects. In: JPT H, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chapter 14. Chichester: Wiley; 2011.

44. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–8.

45. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.